Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
J Tradit Chin Med ; 42(3): 353-363, 2022 06.
Article in English | MEDLINE | ID: mdl-35610004

ABSTRACT

OBJECTIVE: To investigate the effect of slow transit constipation (STC) and spleen deficiency on gut microbiota, and the mechanism underlying the action that the positive drug Maren Runchang (MR) alleviates STC. METHODS: STC was induced, using the cathartic method of Senna and the hunger-fullness disorder method, in ICR mice; one group of model mice was treated with MR (6.24 g/kg). The changes in the general condition, fecal parameters, D-xylose content in the serum, intestinal propulsion rate, and histopathology of the colon were assessed after STC induction in the control, model, and MR groups. Fecal microbiota transplantation (FMT) was performed from STC mice into pseudo germ-free mice. Changes in the contents of substance P (SP), vasoactive intestinal peptide (VIP), and gut microbiota in STC mice and pseudo germ-free mice were assessed after FMT. RESULTS: Compared with the control group, the model mice showed the following results: the time of the first black stool was significantly longer ( 0.01), the number and weight of black stools were significantly reduced within 6 h ( 0.05), the D-xylose content in the serum was significantly reduced ( < 0.05), the intestinal propulsion rate decreased ( < 0.01), the content of VIP in colon tissue significantly increased ( < 0.05), and SP content in the colon tissue significantly decreased ( < 0.01); moreover, the colon showed significant inflame-mation and injury. Furthermore, the abundance of Firmicutes was increased, the abundance of Bacteroides decreased, and the abundance of decreased, while the abundance of the conditional pathogenic bacteria and Klebsiella increased. However, after treatment with MR, the time of the first black stool decreased (0.01), the number of black stools within 6 h increased, and the intestinal propulsion rate increased ( < 0.05). Moreover, the content of D-xylose in the serum and the content of VIP in colon tissue significantly decreased ( < 0.05), the content of SP in colon tissue significantly increased ( < 0.01), and colon inflammation significantly improved. Additionally, the abundance of Firmicutes decreased, and the abundance of Bacteroides increased. The abundance of increased, and the abundance of decreased. In the model + FMT group, compared with control + FMT group, the content of VIP in colon tissue decreased ( < 0.05), the content of SP in colon tissue significantly increased ( < 0.01), and the abundance of probiotics, such as , decreased. In the MR + FMT group, compared with the model + FMT group, the content of VIP in colon tissue increased, the content of SP in colon tissue significantly decreased ( < 0.01), and the abundance of probiotics increased. CONCLUSIONS: STC mice with spleen deficiency show a decreased abundance of beneficial bacteria, such as , and an increased abundance of the conditional pathogenic bacteria . Furthermore, the mechanism of action of MR in treating STC may involve the regulation of intestinal movement, reduction of intestinal inflammation, elevation of intestinal absorption, and regulation of gut microbiota.


Subject(s)
Gastrointestinal Microbiome , Animals , Constipation/drug therapy , Humans , Inflammation , Mice , Mice, Inbred ICR , Pilot Projects , Spleen , Xylose/therapeutic use
2.
FASEB J ; 35(11): e21977, 2021 11.
Article in English | MEDLINE | ID: mdl-34613640

ABSTRACT

Xylo-oligosaccharide (XOS), which is considered as a potential prebiotic, exhibits multiple beneficial effects on modulation of gut microbiota, strength of intestinal barrier, and inhibition of intestinal inflammation. The objective of this study is to investigate whether XOS protects against Salmonella infection by modulating gut microbiota, enhancing the intestinal barrier, and resisting colonization. C57BL/6 male mice received water supplementation with 5% XOS for 14 days before Salmonella Typhimurium infection. The results showed that XOS suppressed the Salmonella-induced inflammation, but had limited effects on tight junction molecules and mRNA expression of mucus proteins, except for claudin-1 in the colon. Data of 16S rDNA sequencing indicated that XOS modulated gut microbiota composition by significantly stimulating Bifidobacterium animalis (B. animalis), and reducing Salmonella counts. Therefore, the potential protective effects of B. animalis against Salmonella challenge were investigated as well. Bifidobacterium animalis subsp lactis BB-12 (BB12), which could markedly increase in XOS, was selected to treat mice. Similarly, Salmonella-induced inflammatory reactions were alleviated by BB12 but tight junction molecules and mucin proteins in the colonic tissues were not affected. Administration of BB12 remarkably decreased the copies of Salmonella in cecal digesta post Salmonella infection. Additionally, the decrease concentrations of cecal propionate and total short-chain fatty acids (SCFAs) in Salmonella-infected mice were reversed by BB12 treatment, and propionate performed a strong inhibitory effect on Salmonella growth in vitro. Besides that, BB12 could directly restrict Salmonella proliferation in vitro. Moreover, BB12 reduced the adhesion ability of Salmonella on the Caco-2 cells model. Our results suggest that XOS could be considered as a candidate of functional food to protect against Salmonella infection by stimulating Bifidobacterium, which then resists Salmonella colonization by maintaining the intestinal SCFAs levels and suppressing adhesibility.


Subject(s)
Bifidobacterium/drug effects , Inflammation/drug therapy , Probiotics , Salmonella Infections/drug therapy , Salmonella typhimurium/drug effects , Xylose , Animals , Gastrointestinal Microbiome/drug effects , Intestines/microbiology , Male , Mice , Mice, Inbred C57BL , Probiotics/pharmacology , Probiotics/therapeutic use , Xylose/analogs & derivatives , Xylose/pharmacology , Xylose/therapeutic use
3.
Life Sci ; 260: 118335, 2020 Nov 01.
Article in English | MEDLINE | ID: mdl-32846167

ABSTRACT

The SARS-Cov-2 pandemic that currently affects the entire world has been shown to be especially dangerous in the elderly (≥65 years) and in smokers, with notably strong comorbidity in patients already suffering from chronic diseases, such as Type 2 diabetes, cancers, chronic respiratory diseases, obesity, and hypertension. Inflammation of the lungs is the main factor leading to respiratory distress in patients with chronic respiratory disease and in patients with severe COVID-19. Several studies have shown that inflammation of the lungs in general and Type 2 diabetes are accompanied by the degradation of glycosaminoglycans (GAGs), especially heparan sulfate (HS). Several studies have also shown the importance of countering the degradation of HS in lung infections and Type 2 diabetes. D-xylose, which is the initiating element for different sulfate GAG chains (especially HS), has shown regeneration properties for GAGs. D-xylose and xylitol have demonstrated anti-inflammatory, antiglycemic, antiviral, and antibacterial properties in lung infections, alone or in combination with antibiotics. Considering the existing research on COVID-19 and related to D-xylose/xylitol, this review offers a perspective on why the association between D-xylose and antibiotics may contribute to significantly reducing the duration of treatment of COVID-19 patients and why some anti-inflammatory drugs may increase the severity of COVID-19. A strong correlation with scurvy, based on gender, age, ethnicity, smoking status, and obesity status, is also reviewed. Related to this, the effects of treatment with plants such as Artemisia are also addressed. CHEMICAL COMPOUNDS: D-xylose; xylitol; l-ascorbic Acid; D-glucuronic acid; N-acetylglucosamine; D-N-acetylglucosamine; N-acetylgalactosamine; galactose.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Betacoronavirus/drug effects , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Severity of Illness Index , Xylose/therapeutic use , Betacoronavirus/isolation & purification , COVID-19 , Comorbidity , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Humans , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , SARS-CoV-2 , Xylose/metabolism , COVID-19 Drug Treatment
4.
ACS Appl Mater Interfaces ; 8(7): 4456-66, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26824739

ABSTRACT

Developing biocompatible tissue adhesives with high adhesion properties is a highly desired goal of the tissue engineering due to adverse effects of the sutures. Therefore, our work involves synthesis, characterization, adhesion properties, protein adsorption, in vitro biodegradation, in vitro and in vivo biocompatibility properties of xylose-based semisynthetic polyurethane (NPU-PEG-X) bioadhesives. Xylose-based semisynthetic polyurethanes were developed by the reaction among 4,4'-methylenebis(cyclohexyl isocyanate) (MCI), xylose and polyethylene glycol 200 (PEG). Synthesized polyurethanes (PUs) showed good thermal stability and high adhesion strength. The highest values in adhesion strength were measured as 415.0 ± 48.8 and 94.0 ± 2.8 kPa for aluminum substrate and muscle tissue in 15% xylose containing PUs (NPU-PEG-X-15%), respectively. The biodegradation of NPU-PEG-X-15% was also determined as 19.96 ± 1.04% after 8 weeks of incubation. Relative cell viability of xylose containing PU was above 86%. Moreover, 10% xylose containing NPU-PEG-X (NPU-PEG-X-10%) sample has favorable tissue response, and inflammatory reaction between 1 and 6 weeks implantation period. With high adhesiveness and biocompatibility properties, NPU-PEG-X can be used in the medical field as supporting materials for preventing the fluid leakage after abdominal surgery or wound closure.


Subject(s)
Biocompatible Materials/chemistry , Tissue Adhesives/chemistry , Tissue Engineering , Biocompatible Materials/therapeutic use , Humans , Microscopy, Atomic Force , Polyethylene Glycols/chemistry , Polyurethanes/chemistry , Polyurethanes/therapeutic use , Surface Properties , Tissue Adhesives/therapeutic use , Xylose/chemistry , Xylose/therapeutic use
5.
Nutr Res ; 35(7): 626-36, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26088373

ABSTRACT

D-Xylose, a natural pentose, has been reported to reduce postprandial glucose levels, although its effect on lipid metabolism has not been investigated. Therefore, this study hypothesized that d-xylose, as an alternative sweetener, suppresses adipogenesis and lipid metabolism by regulating blood lipid profiles, blood glucose levels, and related gene expression in high-fat diet (HFD)-induced obese mice. Mice were fed a normal diet, a 60% HFD diet, or an HFD with 5% or 10% of the total sucrose content supplemented with d-xylose (Xylo 5 and Xylo 10 diets, respectively). Weight gain, food intake, and serum lipid levels for each group were measured. After 12 weeks, histopathology of liver sections and assays of gene expression related to adipogenesis and lipid metabolism in visceral fat and liver tissues were analyzed. Body weight gain; fasting blood glucose levels; weights of subcutaneous and visceral adipose tissues; and serum biochemical markers, including total cholesterol and low-density lipoprotein cholesterol, low-/high-density lipoprotein, and total cholesterol/high-density lipoprotein, were significantly lowered in the Xylo 5 and Xylo 10 groups. In addition, d-xylose supplementation resulted in the down-regulation of adipogenesis-related genes, including sterol regulatory element-binding protein 1C, fatty acid synthase, adipocyte protein 2, and CCAAT/enhancer-binding protein α in visceral adipose tissues. Histopathologically, Xylo 5 and Xylo 10 supplementation reduced HFD-induced fat accumulation in the liver and decreased expressions of fatty acid synthase and peroxisome proliferator-activated receptor γ. D-Xylose supplementation also enhanced lipid oxidation by increasing expressions of carnitine palmitoyltransferase 1A; cytochrome P450, family 4, subfamily a, polypeptide 10; and acyl-CoA oxidase. In conclusion, our finding suggests that d-xylose may help prevent or attenuate the progression of obesity-related metabolic disorders by alleviating adipogenesis and dyslipidemia and improving lipid oxidation.


Subject(s)
Adipogenesis/drug effects , Adipose Tissue/drug effects , Dietary Supplements , Lipid Metabolism/drug effects , Liver/drug effects , Obesity , Xylose/pharmacology , Adipogenesis/genetics , Adipose Tissue/metabolism , Animals , Body Weight/drug effects , Cholesterol/blood , Diet, High-Fat/adverse effects , Down-Regulation , Dyslipidemias/blood , Dyslipidemias/drug therapy , Dyslipidemias/genetics , Dyslipidemias/pathology , Lipid Metabolism/genetics , Lipolysis/drug effects , Lipolysis/genetics , Lipoproteins/blood , Liver/metabolism , Liver/pathology , Male , Mice, Inbred C57BL , Mice, Obese , Obesity/blood , Obesity/drug therapy , Obesity/etiology , Obesity/genetics , Sweetening Agents/pharmacology , Sweetening Agents/therapeutic use , Xylose/therapeutic use
6.
Diabetes Care ; 36(7): 1913-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23359361

ABSTRACT

OBJECTIVE: Macronutrient "preloads" can reduce postprandial glycemia by slowing gastric emptying and stimulating glucagon-like peptide-1 (GLP-1) secretion. An ideal preload would entail minimal additional energy intake and might be optimized by concurrent inhibition of dipeptidyl peptidase-4 (DPP-4). We evaluated the effects of a low-energy D-xylose preload, with or without sitagliptin, on gastric emptying, plasma intact GLP-1 concentrations, and postprandial glycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twelve type 2 diabetic patients were studied on four occasions each. After 100 mg sitagliptin (S) or placebo (P) and an overnight fast, patients consumed a preload drink containing either 50 g D-xylose (X) or 80 mg sucralose (control [C]), followed after 40 min by a mashed potato meal labeled with (13)C-octanoate. Blood was sampled at intervals. Gastric emptying was determined. RESULTS: Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P < 0.01 for each) and were lowest after SX (P < 0.05 for each), while overall blood glucose was lower after SX than PC (P < 0.05). The postprandial insulin-to-glucose ratio was attenuated (P < 0.05) and gastric emptying was slower (P < 0.01) after D-xylose, without any effect of sitagliptin. Plasma GLP-1 concentrations were higher after D-xylose than control only before the meal (P < 0.05) but were sustained postprandially when combined with sitagliptin (P < 0.05). CONCLUSIONS: In type 2 diabetes, acute administration of a D-xylose preload reduces postprandial glycemia and enhances the effect of a DPP-4 inhibitor.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide 1/blood , Pyrazines/therapeutic use , Triazoles/therapeutic use , Xylose/therapeutic use , Aged , Blood Glucose/metabolism , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Enzyme-Linked Immunosorbent Assay , Female , Gastric Emptying/drug effects , Humans , Insulin/blood , Male , Middle Aged , Postprandial Period , Radioimmunoassay , Sitagliptin Phosphate
7.
J Med Chem ; 52(20): 6201-4, 2009 Oct 22.
Article in English | MEDLINE | ID: mdl-19785435

ABSTRACT

The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Sodium-Glucose Transporter 2 Inhibitors , Xylose/analogs & derivatives , Xylose/pharmacology , Animals , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/urine , Drug Discovery , Glucose/metabolism , Humans , Mice , Substrate Specificity , Xylose/administration & dosage , Xylose/therapeutic use
8.
Transplant Proc ; 41(1): 55-6, 2009.
Article in English | MEDLINE | ID: mdl-19249474

ABSTRACT

INTRODUCTION: The shortage of organs in the last 20 years is stimulating the development of new strategies to expand the pool of donors. The harvesting of a graft from non-heart-beating donors (NHBDs) has been successfully proposed for kidney and liver transplantation. To our knowledge, no studies are available for small bowel transplantation using NHBDs. In an experimental setting of small bowel transplantation, we studied the feasibility of using intestinal grafts retrieved from NHBDs. MATERIALS AND METHODS: Twenty five Large White piglets underwent total orthotopic small bowel transplantation and were randomly divided as follow: NHBD group (n = 15) received grafts from NHBDs; heart-beating donor (HBD) group (n = 10) received grafts from HBDs. The NHBD pigs were sacrificed inducing the cardiac arrest by a lethal potassium injection. After 20 minutes (no touch period = warm ischemia), they underwent cardiac massage, laparotomy, and aorta cannulation for flushing and cooling the abdominal organs. In HBDs, the cardiac arrest was induced at the time of organ cold perfusion. In both groups, immunosuppression was based on tacrolimus oral monotherapy. The animals were observed for 30 days. The graft absorptive function was studied at day 30 using the D-xylose absorption test. Histological investigation included HE (Hematoxilin and Eosin) microscopical analysis and immunohistological staining. RESULTS: Animals in the NHBD group died due to infection (n = 3), acute cellular rejection (n = 2), technical complications (n = 2), and intestinal failure (n = 8). In the HBD group, all animals but two were alive at the end of the study. The D-xylose absorption was significantly lower among the NHBD compared with the HBD group (P < .05). CONCLUSIONS: This study confirmed that intestinal mucosa is sensitive to ischemic injury. When the intestinal graft is harvested from NHBDs, the infectious-related mortality was higher and the absorptive function lower. Histological examination confirmed a higher grade of ischemic injury in the NHBD grafts that correlated with the clinical data. Therefore, this experimental study suggested that non-heart-beating donation may not be indicated for small bowel transplantation.


Subject(s)
Intestine, Small/transplantation , Animals , Body Weight , Brain Death , Graft Survival , Heart Arrest/chemically induced , Immunosuppressive Agents/therapeutic use , Intestinal Mucosa/pathology , Ischemia/etiology , Living Donors , Models, Animal , Potassium/toxicity , Swine , Time Factors , Tissue Donors , Transplantation, Homologous , Xylose/therapeutic use
9.
Antimicrob Agents Chemother ; 35(9): 1799-803, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1952851

ABSTRACT

Water activity and bacterial growth inhibition have been studied in formulations comprising either sucrose or xylose along with polyethylene glycol 400 and hydrogen peroxide. The pastes are chemically stable for 6 months if stored at 2 to 8 degrees C and have been shown to lower water activity to levels below those essential for bacterial growth and to be bactericidal even when diluted up to 50% with serum. Of the organisms tested, Staphylococcus aureus proved the least susceptible to the bactericidal effects of these pastes, and candida and gram-negative organisms proved the most susceptible. Pastes without hydrogen peroxide were less rapidly bactericidal than pastes with hydrogen peroxide, while polyethylene glycol 400 itself was found to have considerable antimicrobial activity. It is suggested that sucrose paste may be of benefit as a treatment for infected and malodorous wounds.


Subject(s)
Hydrogen Peroxide/therapeutic use , Polyethylene Glycols/therapeutic use , Sucrose/therapeutic use , Water , Wound Infection/drug therapy , Xylose/therapeutic use , Animals , Drug Combinations , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Ointments
10.
Arch. domin. pediatr ; 25(1): 7-9, ene.-abr. 1989. tab
Article in Spanish | LILACS | ID: lil-103896

ABSTRACT

Se estudiaron 50 pacientes, 25 eran eutróficos y 25 con Diarrea de Evolución Prolongada (DEP). A cada caso se le aplicó la prueba de absorción de D-Xilosa, administrando 5 gm de la sustancia en 100 ml de agua vía oral y midiendo la concentración sérica 1 hora después. Los niños eutróficos tuvieron promedio de D-xilosa en suero de 29.4 ñ 7.3 mg/dl, mientras que los afectados por DEP mostraron valor promedio de 19.0 ñ 8.6 mg/dl, p < 0.01. Se concluye que los niños con DEP, muestran una alteración en la absorción de esta pentosa


Subject(s)
Infant , Child, Preschool , Humans , Male , Diarrhea/drug therapy , Xylose/blood , Xylose/therapeutic use , Chronic Disease
12.
Am J Dis Child ; 136(5): 448-51, 1982 May.
Article in English | MEDLINE | ID: mdl-7081163

ABSTRACT

Gastric emptying in normal newborns was studied with use of a double marker technique. The volume of 200 to 400 mOsm carbohydrate solutions emptied from the stomach in 30 minutes was determined. To evaluate isocaloric solutions of different osmolalities, the osmolality of a 400-mOsm glucose solution was decreased to 300 and 200 mOsm/L by replacing a portion of the glucose with glucose oligosaccharides (GOSs). Because GOSs could be rapidly hydrolyzed in the duodenum, the effect of osmolality alone was studied by adding xylose to a 200-mOsm glucose solution to increase the osmolality to 300 and 400 mOsm/L. The volumes of the various solutions emptied in 30 minutes were not significantly different. These findings suggest that decreasing formula osmolality from 400 to 200 mOsm offers no intrinsic advantage with regard to gastric emptying.


Subject(s)
Carbohydrates/therapeutic use , Gastric Emptying , Infant Food , Infant, Newborn , Duodenum/physiology , Glucose/therapeutic use , Humans , Oligosaccharides/therapeutic use , Osmolar Concentration , Xylose/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...